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AbstrACt
Introduction Haemorheological and haemostatic 
changes predispose to the development of arterial and 
venous thrombotic events; however, limited information is 
available on the status of these changes in coeliac disease 
(CeD) and inflammatory bowel disease (IBD). In this study, 
we aim to describe the haemorheological and haemostatic 
profiles of CeD and IBD patients in a Hungarian cohort of 
patients to investigate whether any alterations contribute 
to elevated thrombotic risk.
Methods and analysis This is a case–control study 
involving newly diagnosed and followed CeD and IBD 
patients with age-matched and sex-matched non-CeD, 
non-IBD subjects with an allocation ratio of 1:1:1. After 
informed consent is obtained, a detailed medical history 
will be collected, including venous and arterial thrombotic 
risk factors and medications. Symptoms in CeD patients 
will be assessed with the Gastrointestinal Symptoms 
Rating Scale, and disease activity in IBD patients will be 
determined by disease-specific scores. Dietary adherence 
will be assessed among CeD patients with a thorough 
interview together with a measurement of self-reported 
adherence, dietary knowledge and urine analysis 
(detection of gluten immunogenic peptides). In addition 
to routine laboratory parameters, haemorheological (ie, 
erythrocyte deformability and aggregation, viscosity of 
whole blood and plasma) and haemostatic parameters 
(eg, protein C, protein S and antithrombin) with 
immunological indicators (ie, coeliac-specific serology 
and antiphospholipid antibodies) will be measured from 
venous blood for every participant. Primary and secondary 
outcomes will be haemorheological and haemostatic 
parameters, respectively. Univariate and multivariate 
statistics will be used to compare CeD and IBD patients to 
control subjects. Subgroup analysis will be performed by 
disease type in IBD, (Crohn’s disease and ulcerose colitis), 
dietary adherence in CeD, and disease activity in IBD and 
CeD.
Ethics and dissemination The study was approved by the 
Regional and Local Research Ethics Committee, University 
of Pécs (Ref. No. 6917). Findings will be disseminated at 
research conferences and in peer-reviewed journals.
trial registration number ISRCTN49677481.
IntroduCtIon
Immune-mediated disorders may affect 
5%–7% of the population.1 These disorders 
strengths and limitations of this study
 ► Immune-mediated bowel diseases are associat-
ed with an increased risk of arterial and venous 
thrombosis, but specific haemorheological and hae-
mostatic alterations are understudied in coeliac dis-
ease (CeD)  and incomplete in inflammatory bowel 
disease (IBD).
 ► This case–control study prospectively recruits new-
ly diagnosed and followed-up cases of CeD and 
IBD  with age-matched and sex-matched controls 
(the allocation ratio will be 1:1:1, respectively) to 
investigate clinical and laboratory alterations pre-
disposing to thrombosis.
 ► Laboratory tests include the measurement of hae-
morheological (ie, erythrocyte aggregation and 
deformability, plasma and whole blood viscosity), 
haemostatic parameters (eg, levels of fibrinogen, 
prothrombin time, protein C, protein S and antithrom-
bin) and immunological indicators (eg, coeliac-spe-
cific serology and antiphospholipid antibodies).
 ► Patients will be divided by disease activity into active 
and inactive.
 ► Results should be interpreted with caution due to the 
single-centre nature and case–control design of the 
study.
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frequently share pathways in pathogenesis as well as 
organ manifestations. Coeliac disease (CeD) and inflam-
matory bowel disease (IBD) are systemic disorders, 
primarily affecting the intestines.2 They impose a signif-
icant burden of complications and concomitant diseases 
on patients during the disease course.
CeD is a chronic, immune-mediated disorder, which 
develops on gluten ingestion in genetically susceptible 
individuals.3 Global prevalence of CeD is around 1% 
with geographical differences ranging from 0.14% up 
to 5.7%.3 The clinical presentation can be divided into 
classic, non-classic and asymptomatic forms.4 Diagnosing 
asymptomatic and atypical cases is challenging but 
important, because the disease course of these cases may 
be alike.5
IBD—clinically classified as Crohn’s disease or ulcer-
ative colitis—is a chronic, relapsing disorder, which 
develops as a result of the interaction between environ-
mental and genetic factors, leading to immunological 
responses and inflammation in the gastrointestinal tract.6 
IBD is a less frequent entity than CeD: the increasing 
prevalence of ulcerative colitis and Crohn’s disease may 
reach 0.5% and 0.3% in Europe, respectively.7 8
Immune-mediated disorders may be associated with 
haemorheological9–11 and haemostatic changes,12–14 
thereby contributing to an increased risk of thrombotic 
events.15 This increased risk is manifested in CeD16 and 
IBD.17 Mechanisms of thrombophilia in immune-medi-
ated disorders are complex, and acquired factors seem 
important.18 An altered haemorheological profile as well 
as the altered levels or function of pro-coagulant and 
anticoagulant proteins, altered activity of clotting factors 
contribute to the development of arterial and venous 
thrombotic events.19–23
Clinical presentation of CeD-associated hypercoagu-
lability includes a wide variety of thrombosis at venous 
sites, pulmonary embolism, atheroembolism (stroke) 
and obstetric complications.24 25 A single retrospec-
tive publication examined haemostatic alterations in 
a small cohort of patients: sporadic cases of protein C 
and protein S deficiency (due to vitamin K malabsorp-
tion), hyperhomocysteinaemia, and antiphospholipid 
antibodies were identified.26 No studies have assessed 
the haemorheological changes in CeD. The multifacto-
rial aetiology of thrombosis may embrace the interplay 
of malabsorption (vitamin and mineral deficiencies, eg, 
vitamin B12 and K deficiency), thrombophilic autoan-
tibodies [anti-tissue transglutaminase (tTG) and anti-
phospholipid antibodies], hyperhomocysteinaemia, 
endothelial dysfunction, accelerated atherosclerosis, 
thrombocytosis and thrombocyte dysfunction, hyper-
viscosity, and genetics.24 26–31 Immune-mediated comor-
bidities (‘autoimmune traits’), such as antiphospholipid 
syndrome, may contribute to the elevated thrombotic risk 
as well.29 In addition, ingestion of trace amounts of gluten 
may maintain a continuous pro-inflammatory response.32
IBD is associated with venous thrombosis and pulmo-
nary embolism as well as with the cardiovascular 
consequences of atherosclerosis, ie, stroke and myocar-
dial infarction.33 34 A significant decline in anticoagulant 
mechanism is well-established and there are sporadic 
reports on activity-dependent prothrombotic haemorhe-
ological changes.35–38 However, while individual studies 
have focused on single outcomes of laboratory parame-
ters, none of them have assessed the complete haemorhe-
ological profile of patients.39–42 Other risk factors include 
immobilisation, surgical interventions, glucocorticoid 
therapy, vitamin deficiencies, hyperhomocysteinaemia 
and chronic inflammation alone or in conjunction with 
the factors above.43 44 In the case of IBD, disease activity 
may be a crucial determinant of thrombotic risk.34
scope and objectives
No studies have assessed haemorheological and haemo-
static parameters within a study to provide an overall view 
of thrombotic risk. Since our knowledge of haemorhe-
ological and haemostatic changes is limited in CeD and 
IBD, this study aims to carry out a comprehensive evalu-
ation of venous and arterial prothrombotic alterations in 
these pro-inflammatory diseases in a Hungarian cohort 
of patients.
1. Primary objective.
 – To identify a link between prothrombotic haemor-
heological and haemostatic alterations and two 
common immune-mediated diseases (CeD and 
IBD).
2. Secondary objective.
 – To investigate the effect of disease activity on the 
haemorheological and haemostatic profiles of CeD 
and IBD patients.
 – To find an association between the dietary adher-
ence of CeD patients and the haemorheological and 
haemostatic alterations.
 – To assess the modifying effect of immunosuppres-
sant drugs in IBD on the haemorheological and 
haemostatic profiles.
MEthods And AnAlysIs
design
This is a case–control study with prospective recruitment 
of CeD and IBD patients with non-CeD, non-IBD control 
subjects. The study does not change the routine manage-
ment of subjects included (for the WHO checklist, see 
table 1). The study protocol was planned in accordance 
with the Standard Protocol Items: Recommendations for 
Interventional Trials 2013 Statement.45
trial organisation and steering committee
The Centre for Translational Medicine at the University of 
Pécs, which was established to advance medical research 
in gastroenterology, is the co-ordinator and designer of 
the HERMES study. The centre is experienced in running 
investigator-initiated clinical trials.46 A steering committee 
will be set up to supervise the entire study process. The 
principal investigator (JB) and the Trial Coordinator 
(ZS) are responsible for organising patient recruitment, 
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data collection, sample collection, shipping, and storage, 
biochemical analysis, and the publication of study results.
Population and eligibility
We will include CeD patients, IBD patients, and non-CeD, 
non-IBD control subjects. Eligibility criteria will be as 
follows:
a. Inclusion criteria (applies to all subjects).
 – Blood collection must be indicated with medical 
conditions.
 – Signed informed consent.
b. Inclusion criteria (applies to specific cohorts of 
patients).
 – CeD patients: biopsy-confirmed newly diagnosed or 
followed patients (with or without adhering to a glu-
ten-free diet) aged ≥18 years; the establishment of a 
Table 1 WHO checklist
Data category Information
Primary registry and trial identifying number ISRCTN49677481
Date of registration in primary registry 05/03/2018
Secondary identifying numbers None
Source(s) of monetary or material support University of Pécs Medical School; Momentum Grant from the Hungarian 
Academy of Sciences (LP2014-10/2014); Highly Cited Publication Grant (KH 
125678) from the National Research Development and Innovation Office; GINOP 
2.3.2-15-2016-00048 Stay Alive, EFOP 3.6.2-16-2017-00006 Live Longer, and 
EFOP-3.6.3-VEKOP-16-2017-00009; Translational Medicine Foundation; and 
New National Excellence Programme, Ministry of Human Capacities (ÚNKP-
17–3-II, ÚNKP-18–3-I)
Primary sponsor None
Secondary sponsor(s) None
Contact for public queries Zsolt Szakács, MD, szakacs.zsolt@pte.hu
Contact for scientific queries Judit Bajor, MD, bajor.judit@pte.hu
Public title Investigation of haemorheological and haemostatic alterations in coeliac disease 
and inflammatory bowel disease in comparison with healthy subjects: A case–
control study (HERMES)
Scientific title Haemorheological and haemostatic alterations in coeliac disease and 
inflammatory bowel disease in comparison with non-coeliac, non-IBD subjects: A 
case–control study (HERMES)
Countries of recruitment Hungary
Health condition(s) or problem(s) studied Coeliac disease and inflammatory bowel disease
Intervention(s) Questionnaires (thrombophilia, dietary adherence, disease activity), urine 
collection (dietary adherence—urine-gluten immunogenic peptide detection), 
blood collection (haemorheological, haemostatic and immunological tests 
complemented with routine laboratory panel)
Key inclusion and exclusion criteria Inclusion criteria: adult patients (≥18 years of age) suffering from biopsy-
confirmed newly diagnosed or treated coeliac disease (by ESPHGAN, ACG, 
WGO guidelines), or from inflammatory bowel disease (by ECCO guidelines), and 
non-coeliac, non-IBD subjects
Exclusion criteria: chronic diseases (chronic kidney diseases, liver cirrhosis, heart 
failure, active malignant diseases), acute diseases within 2 weeks of inclusion, 
pregnancy, thrombotic events within 1 year, systematic lupus erythematosus, and 
use of oral anticoagulants or antiplatelet therapy
Study type Observational
Date of first enrolment 30/5/2018
Target sample size First phase: 50 coeliac and 50 IBD patients plus control (1–3 for each patient). 
Second phase: target number is determined by power calculation
Recruitment status Ongoing
Primary outcome(s) Haemorheological test results
Key secondary outcomes Haemostatic test results
IBD, inflammatory bowel disease.
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diagnosis should meet the current guidelines (Eu-
ropean Society for Paediatric Gastroenterology 
Hepatology and Nutrition (ESPHGAN) and Amer-
ican College of Gastroenterology (ACG)).3 47 48
 – IBD patients: newly diagnosed or followed-up pa-
tients (with active or remitting disease) aged ≥18 
years (not following a gluten-free diet); the estab-
lishment of a diagnosis should meet the current 
guidelines (European Crohn's and Colitis Organi-
sation (ECCO).49 50
 – Non-CeD, non-IBD control subjects: individuals 
aged ≥18 years (not following a gluten-free diet) in 
whom CeD and IBD can be excluded according to 
the recent guidelines.3 47–50
c. Exclusion criteria (applies to all subjects).
 – Chronic conditions.
 – Estimated glomerular filtration rate calculated 
with the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula is <60 mL/
min/1.73 m2 (CKD3 or more severe kidney fail-
ure).
 – Liver cirrhosis in Child–Pugh B–C.
 – Heart failure (New York Heart Association 
(NYHA) III–IV).
 – Active malignant diseases.
 – Any acute diseases or invasive procedures within 
2 weeks of recruitment (eg, systemic infection, sur-
gery, or major trauma).
 – Thrombotic events within 1 year of recruitment.
 – Ongoing oral anticoagulant therapy (vitamin K an-
tagonists) and/or antiplatelet drugs.
 – Confirmed systemic lupus erythematosus.
 – Pregnancy.
 – Patients unable to understand the essentials of the 
informed consent.
Flow and timing
All subjects at our academic hospital for a planned 
check-up or referred to the centre for diagnostic purposes 
will be recruited consecutively. The place of recruitment 
will be the Division of Gastroenterology, First Department 
of Medicine, University of Pécs Medical School. This 
tertiary centre provides professional gastroenterological 
care for about 300 000 inhabitants in Baranya County, 
Hungary.
Recruitment of the study population will be managed 
in two phases (see Target number of patient section), 
with the expected recruiting period being between May 
2018 and May 2019 (covering 1 year). Table 2 shows the 
timeline of the study. Patients will be provided with an 
information sheet and must provide written consent 
before sampling. Informed consent will be obtained by 
personnel with a medical degree. Participants may with-
draw from the study for any reason at any time. Consent 
forms and other related documents will be accessible at 
https:// tm- centre. org.
Patients will be monitored by our professional data 
management team throughout the entire process of data 
and biological sample collection to ensure perfect adher-
ence to protocol. Written feedback will be provided to 
patients on the results of the laboratory tests and dietary 
evaluation. If findings indicate, patients will be referred 
Table 2 Schedule for the study
Time point
Study period
Enrolment Allocation Post-allocation
−1 hour 0 +1 hour +1.5 hour +2 hour
Enrolment
  Eligibility screen x
  Informed consent x
  Allocation x
Intervention
  Interview and questionnaire x
  Urine collection x
  Blood collection x
Assessment
  Symptom scores and disease 
activity
x
  Thrombophilia questionnaire x
  Dietary adherence x
  Blood analysis* x
  Urine analysis* ≥†
*After analysis, blood and urine residues will be stored in the biobank.
†Samples will be deep frozen until all participants have been recruited.
 o
n
 January 18, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026315 on 23 March 2019. Downloaded from 
5Szakács Z, et al. BMJ Open 2019;9:e026315. doi:10.1136/bmjopen-2018-026315
Open access
to their general practitioners or a specialist for further 
investigation and management.
Measurements
All samples will be collected and questionnaires will be 
administered within 2 hours after allocation. Actions for 
each group are defined and listed in table 3.
Detailed history (including medications for preceding 
3 months) and risk factors of venous and arterial throm-
botic events will be covered with a 15 min thrombophilia 
questionnaire (administered by a person with a medical 
degree).
The Gastrointestinal Symptoms Rating Scale is a tool 
designed to assess the severity of gastrointestinal symp-
toms on a scale of 1–7 (administered by a person with a 
medical degree).51
Disease activity in IBD will be estimated with either 
the (modified) Mayo Score52 or Crohn’s Disease Activity 
Index53 in patients with ulcerative colitis and Crohn’s 
disease, respectively, while tissue transglutaminase (tTG) 
levels will be used to measure the activity of CeD. (Scores 
will be determined by the gastroenterologist enrolling 
the patient.)
Dietary adherence of CeD patients will be estimated 
through (1) a dietary interview conducted by a trained 
dietitian on a scale of 1–10, (2) self-reporting,54 (3) a 
test measuring knowledge of gluten-free foods, (4) urine 
gluten-immunogenic peptides (GIP) detection (details in 
the text) and (5) coeliac-specific serology [tTG and endo-
mysium antibody levels (EMA)].55Patients will be divided 
into those with good and poor dietary adherence based 
on the complex assessment of the above-mentioned data.
All laboratory tests will be performed in the same labo-
ratory (University of Pécs, Hungary) from venous blood. 
Blood samples will be collected in plastic tubes prospec-
tively [2 x BD Vacutainer 10.0 mL (red), 2 x BD Vacutainer 
6.0 mL (purple), 1 x BD Vacutainer 3.0 mL (pink), 1 x BD 
Vacutainer 2.7 mL (blue) and 1 x BD Seditainer 5.0 mL 
(black) for a total of 42.7 mL blood from each patient 
(BD, USA)].
We will measure:
 ► Routine laboratory parameters: bilirubin, urea, creati-
nine, cholesterol (total, high-density and low-density 
lipoproteins), triglyceride, , aspartate aminotrans-
ferase, alanine aminotransferase, alkaline phos-
phatase, gamma-glutamyl transferase, total protein, 
albumin, immunoglobulins, C reactive protein, 
vitamin B12, folic acid, homocysteine, blood counts 
and erythrocyte sedimentation.
 ► Immunological indicators: antiphospholipid anti-
bodies (lupus anticoagulant, cardiolipin IgG/IgA/
IgM, B2-glycoprotein-I IgG/IgA/IgM, prothrombin 
IgG/IgA/IgM) and coeliac-specific antibodies (tTG 
IgA/IgG, EMA IgA).
 ► Haemostatic parameters: prothrombin, thrombin 
time, activated partial thromboplastin time, fibrin-
ogen, antithrombin activity, protein C activity and 
protein S activity.
 ► Haemorheological parameters: erythrocyte aggre-
gation by Myrenne aggregometer (model MA-1, 
Myrenne GmbH, Roetgen, Germany) and Laser-as-
sisted Optical Rotational Cell Analyzer (LORCA, R&R 
Mechatronics, Hoorn, The Netherlands); erythro-
cyte deformability with laser-diffraction ektacytom-
etry with a LORCA; and viscosity of whole blood and 
plasma by Brookfield DV-III Ultra LV Programmable 
rotational viscometer (Brookfield Engineering Labs; 
Middleboro, Mass., USA). The Case Report Form 
providing data about the measurements is presented 
in online supplementary material.
Strict adherence will be kept during the haemorheolog-
ical tests to the guidelines proposed by the International 
Expert Panel for Standardisation of Haemorheological 
Methods.56 The fact that equipment for haemorheo-
logical measurements is not available in other centres 
in Hungary and that blood samples must be processed 
within 2 hours of sampling without freezing restricted our 
expansion of this project to a multicentre study.
An extra tube will be collected and stored for further 
haemostatic measurements (eg, clotting factors) if any 
abnormality of parameters measured is detected.
Midstream urine (at least 100 mL) will be collected in 
sterile urine sample containers. Samples will be stored at 
4°C until transfer to the Biobank at the Institute for Trans-
lational Medicine, University of Pécs Medical School, on 
the day of sampling, where samples will be deep frozen 
at −80°C. After preparation, urine GIP detection will be 
performed with Biomedal (Spain) products.
outcomes
1. Primary.
 – Haemorheological test results (erythrocyte aggre-
gation and deformability, whole blood and plasma 
viscosity).
Table 3 Actions within study
CeD 
patients
IBD 
patients
Control 
subjects
Thrombophilia questionnaire + + +
GSRS + − +
Dietary interview and GFD 
adherence tests
+ − +
Mayo Score/CDAI − + +
Urine GIP detection + − +
Laboratory measures
  Routine parameters + + +
  Haemorheology + + +
  Haemostasis + + +
  Immunological indicators + + +
CDAI, Crohn’s Disease Activity Index; CeD, coeliac disease; 
GFD, gluten-free diet; GIP, gluten-immunogenic peptides; GSRS, 
Gastrointestinal Symptoms Rating Scale; IBD, inflammatory bowel 
disease.
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2. Secondary.
 – Haemostatic test results (antithrombin, protein C, 
protein S), folic acid, and homocysteine levels.
target number of patients
This is a two-phase study. In the first phase, we will enrol 
50 CeD and 50 IBD patients with 50 age- matched and 
sex-matched control subjects; the case–control ratio will 
be 1:1:1, respectively. Then, an interim analysis will be 
performed to calculate the power for the analyses of the 
outcomes. If the power exceeds 80%, recruitment will 
be considered completed; otherwise, recruitment will 
continue until the desired power is reached.
Patient and public involvement
Before starting recruitment, randomly selected CeD and 
IBD patients reviewed the questionnaires and the infor-
mation sheet designed to share details of the study for 
participants to facilitate better understanding.
blinding
Blinding of personnel included in the study is presented 
in table 4.
data management
A subject identification number will be provided consec-
utively to every patient after inclusion. Subject identifica-
tion numbers with sensitive data on patients (including 
the name, insurance number and date of enrolment) 
will be stored in a locked file separately from other data. 
De-identified data will be added to the source documen-
tation stored in locked cabinets. Source documentation 
will be entered in an electronic case report file (e-CRF). 
The principal investigators will ensure that the data in an 
e-CRF are accurate, complete and legible (range checks 
for data values). E-CRFs will be stored on a secured server 
at the Institute for Translational Medicine, University 
of Pécs Medical School. Access to data will be restricted 
through a password system to personnel involved in data 
management. A three-level data check will be continu-
ously performed, and final data will be finally approved 
by the principal investigator to ensure data quality.
To ensure precise data collection, administrative and 
medical staff members will be invited to participate 
in training sessions to familiarise them with the study 
requirements, standardised data recording and biological 
specimen collection.
The de-identified dataset will be delivered for the 
purpose of sharing on request.
statistical analysis
First, descriptive statistics will entail a graphical presen-
tation of data. Continuous variables will be reported as a 
central tendency with a measure of dispersion, while cate-
gorical variables will be reported as absolute and relative 
frequencies. Then, data will be analysed with Student’s 
tests, methods of Variance Analysis, and regression models 
if data are normally distributed; otherwise, non-para-
metric tests will be introduced. χ2 or Fisher’s tests will be 
used to analyse categorical variables. Multivariate anal-
ysis will be used to take the most important thrombotic 
factors into account (eg, the use of oral contraceptives 
and immunosuppressants, previous thrombotic history, 
smoking, comorbidities). A probability of less than 0.05 
indicates a statistically significant difference between 
groups.
Only patients with a full dataset in their haemorheo-
logical and haemostatic profile will be included in the 
analysis. The following comparisons will be done: CeD 
versus control, tTG+CeD versus tTG- CeD, CeD with good 
dietary adherence versus CeD with poor dietary adher-
ence, IBD versus control, active IBD versus remitting IBD 
and Crohn’s disease versus ulcerative colitis.
An interim analysis is planned after recruiting the target 
number of the first phase to calculate power. Audits are 
not necessary due to the case–control design.
biobank and accessory research
After laboratory analysis, urine and blood (whole blood 
and plasma, at least 1 mL each) residues will be stored in 
the Institute for Translational Medicine Biobank at −80°C 
for future studies (for at least 5 years). Additional samples 
will not be taken for storage purposes. Containers will 
be labelled with the subject identification number, and 
samples will be completely de-identified.
CeD patients will be offered an opportunity to 
participate in the ‘Monitoring the prevalence, symp-
toms, complications and family history of CeD and the 
effect of a gluten-free diet—Coeliac registry’ research 
Table 4 Blinding of personnel included in the study
Physician enrolling 
patient
Physician administering 
questionnaires Dietitian Laboratory personnel
Disease activity N/A Blinded Blinded Blinded
Questionnaires Blinded* N/A Blinded Blinded
Dietary interview Blinded* Blinded N/A† Blinded
Laboratory measures Blinded* Blinded Blinded N/A
*The treating physician will immediately access data for safety reasons and act accordingly. Patients will be informed of the laboratory results 
in a letter.
†Dietary education will be provided based on dietary adherence.
N/A, not applicable.
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project (approved by the Scientific and Research Ethics 
Committee of the Medical Research Council, Ref. No. 
45098-2/2016/EKU).
Protocol amendments and disseminating policy
This protocol is the first version completed on 30 May 
2018. If required, the online version will be updated 
in the ISRCTN registry. Major modifications should be 
permitted by the Regional and Local Research Ethics 
Committee.
The trial status is ongoing; recruitment began on 1 May 
2018. The expected date of completion is 31 May 2019.
dIsCussIon
Recent guidelines on CeD do not make any recommen-
dations on how to prevent and manage thrombotic events 
in CeD patients.3 47 Gluten-free diet, which is the only 
approved treatment of the disease, may reduce or elim-
inate some thrombotic risk factors (eg, consequences of 
malabsorption and chronic inflammation) but it is uncer-
tain whether the thrombotic risk completely norma-
lises.57 With respect to malabsorption, intestinal mucosa 
does not recover in a high fraction of patients despite a 
long-term strict diet, particularly in those diagnosed in 
the adulthood.58 Whether CeD patients after a throm-
botic event would benefit from a lifelong anticoagulation 
therapy has remained unclear. The need for thrombo-
prophylaxis under prothrombotic circumstances, such as 
hospitalisation, pregnancy, or immobilisation should be 
further investigated.
IBD guidelines recommend that thromboprophylaxis 
should be considered in all inpatients and outpatients 
with an active disease.59 60 In addition to disease severity, 
the choice of treatment influences the thrombotic risk as 
well.17 A tool of personalised thrombotic risk stratification 
including objective laboratory markers is awaited.
Our results can contribute to expanding our knowl-
edge on the prothrombotic pathophysiological alteration 
in CeD and IBD, thereby providing the basis for future 
research.
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